<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01586871</url>
  </required_header>
  <id_info>
    <org_study_id>1202M09721</org_study_id>
    <secondary_id>U54NS065768</secondary_id>
    <nct_id>NCT01586871</nct_id>
  </id_info>
  <brief_title>Carotid Structure and Function in MPS Syndromes: A Multicenter Study of the Lysosomal Disease Network</brief_title>
  <official_title>Carotid Structure and Function in MPS Syndromes: A Multicenter Study of the Lysosomal Disease Network</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rare Diseases Clinical Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mucopolysaccharidosis (MPS) syndromes are disorders characterized by enzyme deficiencies, and&#xD;
      they have been linked to heart health complications. However, there are currently no proven&#xD;
      markers of heart and artery health for this population. The main purpose of this&#xD;
      observational study is to evaluate the ease and convenience of a non-invasive measurement of&#xD;
      artery function in MPS I, MPS II and MPS VI patients compared to healthy control subjects. An&#xD;
      observational study is a research design meaning that there is no treatment in this study.&#xD;
&#xD;
      The research questions are:&#xD;
&#xD;
        1. Is the artery health of MPS I, II and VI patients different than healthy controls?&#xD;
&#xD;
        2. Is the artery health of MPS VI patients different than MPS I and II patients?&#xD;
&#xD;
      It is hypothesized that MPS patients will have poorer outcomes of artery health compared to&#xD;
      healthy controls.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mucopolysaccharidosis (MPS) syndromes are disorders characterized by enzyme deficiencies. As&#xD;
      a result of the enzyme deficiency, glycosaminoglycans that are normally recycled in a healthy&#xD;
      individual cannot be degraded in the MPS patient. MPS syndromes have been linked to heart&#xD;
      health complications. Complications related to coronary artery stenosis (narrowing) are&#xD;
      recognized as potentially fatal sequelae of untreated and treated MPS. Presently, national&#xD;
      guidelines are largely silent on coronary artery disease risk in this population. There are&#xD;
      currently no validated markers of cardiovascular or coronary artery disease in the MPS&#xD;
      population. The main purpose of this observational study is to evaluate the ease and&#xD;
      convenience of a non-invasive measurement of artery function in MPS I, MPS II and MPS VI&#xD;
      patients compared to healthy control subjects. Exploring the validity and usefulness of this&#xD;
      non-invasive measurement is the first step towards developing validated markers of&#xD;
      cardiovascular or coronary artery disease in the MPS population.&#xD;
&#xD;
      Specific Aim #1: Compare carotid artery intima-media thickness and carotid stiffness in&#xD;
      individuals with MPS I, II, and VI (treated and non-treated) vs. healthy age-and&#xD;
      gender-matched controls. It is hypothesized that MPS patients will have increased carotid&#xD;
      artery thickness and reduced carotid compliance and distensibility compared to healthy&#xD;
      controls.&#xD;
&#xD;
      Specific Aim #2: Compare carotid artery intima-media thickness and carotid stiffness in&#xD;
      individuals with MPS VI vs. I and II and between MPS I patients clinically treated with HSCT&#xD;
      vs. ERT. It is hypothesized that MPS VI will have decreased carotid thickness and increased&#xD;
      carotid compliance and distensibility compared to MPS I and II and that MPS I patients&#xD;
      treated with ERT will have increased carotid thickness and reduced carotid compliance and&#xD;
      distensibility compared to MPS I patients treated with HSCT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Carotid Intima-media Thickness, Measured in Millimeters</measure>
    <time_frame>Baseline</time_frame>
    <description>The carotid intima-media thickness test (CIMT) is a measure used to diagnose the extent of carotid atherosclerotic vascular disease. The test measures the thickness of the inner two layers of the carotid artery-the intima and media-and alerts physicians to any thickening when patients are still asymptomatic. CIMT was measured from the far wall of the left common carotid.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Carotid Cross-sectional Distensibility</measure>
    <time_frame>Baseline</time_frame>
    <description>Carotid distensibility is a measure of carotid artery elasticity that has been introduced as a risk factor for cardiovascular disease. It is defined by the percent change in carotid lumen area from diastole to systole, has the unit of % and is defined by the equation (sD^2 - dD^2/dD^2)*100 where sD is the maximum systolic carotid diameter, dD is the minimum diastolic carotid diameter. Increasing carotid distensibility reflects high carotid distensibility and low stiffness, and vice versa.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carotid Cross-sectional Compliance</measure>
    <time_frame>Baseline</time_frame>
    <description>This is defined by the relative change in carotid lumen area from diastole to systole for a given change in blood pressure, has the unit mm^2/mmHg and is defined by the equation Â¶(sD^2-dD^2)/4*PP where PP is pulse pressure (or systolic blood pressure-diastolic blood pressure). Increasing carotid cross sectional compliance reflects high carotid distensibility and low stiffness, and vice versa.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carotid Incremental Elastic Modulus</measure>
    <time_frame>Baseline</time_frame>
    <description>A way of measuring the elasticity constant of the carotid vessel, has the unit mmHg and is defined by the equation 3(1+sD^2/dD^2)/cross sectional compliance value. In contrast to carotid cross sectional compliance and carotid cross sectional distensibility, increasing carotid incremental elastic modus reflects low carotid distensibility and high thickness.</description>
  </secondary_outcome>
  <enrollment type="Actual">1147</enrollment>
  <condition>Mucopolysaccharidoses</condition>
  <eligibility>
    <study_pop>
      <textblock>
        This is an observational study of 60 individuals with MPS I, II and VI between the ages of&#xD;
        3 and 18. Those participating in this study will be seen for a onetime, one-hour study&#xD;
        visit. Participants will be enrolled at the University of Minnesota, Minneapolis, Minnesota&#xD;
        and Children's Hospital of Orange County, Orange, California.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be between the ages of 3 and 18 years old&#xD;
&#xD;
          -  Be diagnosed with MPS I, MPS II or MPS VI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aaron S Kelly, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://rarediseasesnetwork.org</url>
    <description>Rare Disease Clinical Research Network</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 25, 2012</study_first_submitted>
  <study_first_submitted_qc>April 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2012</study_first_posted>
  <results_first_submitted>November 12, 2020</results_first_submitted>
  <results_first_submitted_qc>January 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 3, 2021</results_first_posted>
  <last_update_submitted>February 5, 2021</last_update_submitted>
  <last_update_submitted_qc>February 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MPS I</keyword>
  <keyword>MPS II</keyword>
  <keyword>MPS IIIA</keyword>
  <keyword>MPS VI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidoses</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a dual-center, cross-sectional assessment of carotid imaging data obtained from 33 patients with biochemically and/or molecularly confirmed MPS Types I, II, III and VI; 560 healthy pediatric control patients; and 554 adult control patients. The pediatric and adult controls were obtained from prior studies of insulin resistance and cardiovascular risk at the University of Minnesota. Clinical data from MPS patients were obtained from chart review.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Pediatric Control Patients</title>
          <description>The pediatric control patients were obtained from prior studies of insulin resistance and cardiovascular risk at the University of Minnesota.</description>
        </group>
        <group group_id="P2">
          <title>Adult Controls</title>
          <description>The adult controls were obtained from prior studies of insulin resistance and cardiovascular risk at the University of Minnesota.</description>
        </group>
        <group group_id="P3">
          <title>MPS Patients</title>
          <description>Clinical data (demographic information, anthropometrics, ethnicity, confirmation of diagnosis, and treatment status) from MPS patients were obtained from chart review. For this project, data from MPS I, MPS II, MPS IIIa and MPS VI was available.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="560"/>
                <participants group_id="P2" count="554"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="560"/>
                <participants group_id="P2" count="554"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pediatric Control</title>
          <description>Healthy pediatric control subjects</description>
        </group>
        <group group_id="B2">
          <title>Adult Control</title>
          <description>Healthy adult control subjects</description>
        </group>
        <group group_id="B3">
          <title>Mucopolysaccharidosis (MPS ) Subjects</title>
          <description>Mucopolysaccharidosis subjects type I, II, IIIA and VI.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="560"/>
            <count group_id="B2" value="554"/>
            <count group_id="B3" value="33"/>
            <count group_id="B4" value="1147"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.14" spread="4.01"/>
                    <measurement group_id="B2" value="39.16" spread="2.24"/>
                    <measurement group_id="B3" value="12.47" spread="4.66"/>
                    <measurement group_id="B4" value="21.59" spread="3.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="259"/>
                    <measurement group_id="B2" value="285"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="554"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="301"/>
                    <measurement group_id="B2" value="269"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <description>measured in centimeters</description>
          <units>centimeters</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="155" spread="18.3"/>
                    <measurement group_id="B2" value="171" spread="12.8"/>
                    <measurement group_id="B3" value="132" spread="16.59"/>
                    <measurement group_id="B4" value="152.66" spread="15.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <description>measured in kilograms</description>
          <units>kilograms</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.8" spread="23.54"/>
                    <measurement group_id="B2" value="86.39" spread="23.33"/>
                    <measurement group_id="B3" value="36.66" spread="16.74"/>
                    <measurement group_id="B4" value="58.95" spread="21.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>Kg/m^2</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.44" spread="5.84"/>
                    <measurement group_id="B2" value="29.46" spread="7.47"/>
                    <measurement group_id="B3" value="20.03" spread="4.50"/>
                    <measurement group_id="B4" value="23.64" spread="5.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic blood pressure</title>
          <units>mm Hg</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106" spread="10.42"/>
                    <measurement group_id="B2" value="125" spread="15.59"/>
                    <measurement group_id="B3" value="106" spread="10.98"/>
                    <measurement group_id="B4" value="112.33" spread="12.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic blood pressure</title>
          <units>mm Hg</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="7.78"/>
                    <measurement group_id="B2" value="71.97" spread="10.39"/>
                    <measurement group_id="B3" value="55" spread="13.73"/>
                    <measurement group_id="B4" value="61.65" spread="10.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Carotid Intima-media Thickness, Measured in Millimeters</title>
        <description>The carotid intima-media thickness test (CIMT) is a measure used to diagnose the extent of carotid atherosclerotic vascular disease. The test measures the thickness of the inner two layers of the carotid artery-the intima and media-and alerts physicians to any thickening when patients are still asymptomatic. CIMT was measured from the far wall of the left common carotid.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pediatric Control</title>
            <description>Healthy pediatric control subjects</description>
          </group>
          <group group_id="O2">
            <title>Adult Control</title>
            <description>Healthy adult control subjects</description>
          </group>
          <group group_id="O3">
            <title>Mucopolysaccharidosis (MPS ) Subjects</title>
            <description>Mucopolysaccharidosis subjects type I, II, IIIA and VI.</description>
          </group>
        </group_list>
        <measure>
          <title>Carotid Intima-media Thickness, Measured in Millimeters</title>
          <description>The carotid intima-media thickness test (CIMT) is a measure used to diagnose the extent of carotid atherosclerotic vascular disease. The test measures the thickness of the inner two layers of the carotid artery-the intima and media-and alerts physicians to any thickening when patients are still asymptomatic. CIMT was measured from the far wall of the left common carotid.</description>
          <units>mm</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="560"/>
                <count group_id="O2" value="554"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="0.04"/>
                    <measurement group_id="O2" value="0.52" spread="0.09"/>
                    <measurement group_id="O3" value="0.56" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Carotid Cross-sectional Distensibility</title>
        <description>Carotid distensibility is a measure of carotid artery elasticity that has been introduced as a risk factor for cardiovascular disease. It is defined by the percent change in carotid lumen area from diastole to systole, has the unit of % and is defined by the equation (sD^2 - dD^2/dD^2)*100 where sD is the maximum systolic carotid diameter, dD is the minimum diastolic carotid diameter. Increasing carotid distensibility reflects high carotid distensibility and low stiffness, and vice versa.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pediatric Control</title>
            <description>Healthy pediatric control subjects</description>
          </group>
          <group group_id="O2">
            <title>Adult Control</title>
            <description>Healthy adult control subjects</description>
          </group>
          <group group_id="O3">
            <title>Mucopolysaccharidosis (MPS ) Subjects</title>
            <description>Mucopolysaccharidosis subjects type I, II, IIIA and VI.</description>
          </group>
        </group_list>
        <measure>
          <title>Carotid Cross-sectional Distensibility</title>
          <description>Carotid distensibility is a measure of carotid artery elasticity that has been introduced as a risk factor for cardiovascular disease. It is defined by the percent change in carotid lumen area from diastole to systole, has the unit of % and is defined by the equation (sD^2 - dD^2/dD^2)*100 where sD is the maximum systolic carotid diameter, dD is the minimum diastolic carotid diameter. Increasing carotid distensibility reflects high carotid distensibility and low stiffness, and vice versa.</description>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="560"/>
                <count group_id="O2" value="554"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.03" spread="8.35"/>
                    <measurement group_id="O2" value="16.33" spread="4.73"/>
                    <measurement group_id="O3" value="28.36" spread="15.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Carotid Cross-sectional Compliance</title>
        <description>This is defined by the relative change in carotid lumen area from diastole to systole for a given change in blood pressure, has the unit mm^2/mmHg and is defined by the equation Â¶(sD^2-dD^2)/4*PP where PP is pulse pressure (or systolic blood pressure-diastolic blood pressure). Increasing carotid cross sectional compliance reflects high carotid distensibility and low stiffness, and vice versa.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pediatric Control</title>
            <description>Healthy pediatric control subjects</description>
          </group>
          <group group_id="O2">
            <title>Adult Control</title>
            <description>Healthy adult control subjects</description>
          </group>
          <group group_id="O3">
            <title>Mucopolysaccharidosis (MPS ) Subjects</title>
            <description>Mucopolysaccharidosis subjects type I, II, IIIA and VI.</description>
          </group>
        </group_list>
        <measure>
          <title>Carotid Cross-sectional Compliance</title>
          <description>This is defined by the relative change in carotid lumen area from diastole to systole for a given change in blood pressure, has the unit mm^2/mmHg and is defined by the equation Â¶(sD^2-dD^2)/4*PP where PP is pulse pressure (or systolic blood pressure-diastolic blood pressure). Increasing carotid cross sectional compliance reflects high carotid distensibility and low stiffness, and vice versa.</description>
          <units>mm^2*mm Hg-1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="560"/>
                <count group_id="O2" value="554"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.05"/>
                    <measurement group_id="O2" value="0.11" spread="0.04"/>
                    <measurement group_id="O3" value="0.14" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Carotid Incremental Elastic Modulus</title>
        <description>A way of measuring the elasticity constant of the carotid vessel, has the unit mmHg and is defined by the equation 3(1+sD^2/dD^2)/cross sectional compliance value. In contrast to carotid cross sectional compliance and carotid cross sectional distensibility, increasing carotid incremental elastic modus reflects low carotid distensibility and high thickness.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pediatric Control</title>
            <description>Healthy pediatric control subjects</description>
          </group>
          <group group_id="O2">
            <title>Adult Control</title>
            <description>Healthy adult control subjects</description>
          </group>
          <group group_id="O3">
            <title>Mucopolysaccharidosis (MPS ) Subjects</title>
            <description>Mucopolysaccharidosis subjects type I, II, IIIA and VI.</description>
          </group>
        </group_list>
        <measure>
          <title>Carotid Incremental Elastic Modulus</title>
          <description>A way of measuring the elasticity constant of the carotid vessel, has the unit mmHg and is defined by the equation 3(1+sD^2/dD^2)/cross sectional compliance value. In contrast to carotid cross sectional compliance and carotid cross sectional distensibility, increasing carotid incremental elastic modus reflects low carotid distensibility and high thickness.</description>
          <units>mm Hg</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="560"/>
                <count group_id="O2" value="554"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="951" spread="379.84"/>
                    <measurement group_id="O2" value="1859" spread="755.3"/>
                    <measurement group_id="O3" value="1341" spread="817.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>This is a chart review study that collected data at only one timepoint.</time_frame>
      <desc>There were no adverse events to be reported as this is a chart review study.</desc>
      <group_list>
        <group group_id="E1">
          <title>MPS Patients</title>
          <description>Individuals with MPS disease (17 MPS I, 9 MPS II, 4 MPS IIIA , 3 MPS VI)</description>
        </group>
        <group group_id="E2">
          <title>Pediatric Controls</title>
          <description>Healthy pediatric control subjects</description>
        </group>
        <group group_id="E3">
          <title>Adult Controls</title>
          <description>Healthy adult control subjects</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="560"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="560"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="560"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Aaron Kelly PhD</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>612-626-3492</phone>
      <email>kelly105@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

